← All trials
NCT04634513
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Dec 20, 2024
- Completion date
- Oct 31, 2025
- First posted
- Nov 18, 2020
- Last posted
- Nov 1, 2021
- Enrollment
- 54
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MarylandLead sponsor
- University of MarylandOverall official - principal investigator
- University of MarylandReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.